Filing Details
NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) filed a Form 8-K with the Securities and Exchange Commission on August 17, 2026, disclosing a material event.
8k filedNASDAQ:NRXP
NRX Pharmaceuticals, Inc. (NRXP) Reports Material Event to SEC
NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) filed a Form 8-K with the Securities and Exchange Commission on August 17, 2026, disclosing a material event.
At publication ·
What changed
NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- NRX Pharmaceuticals filed a Form 8-K with the SEC on August 17, 2026, disclosing a material event, though the specific nature of the event is not detailed in this article.
- The company's stock trades at $3.43 with a market capitalization of $37.9 million as of the filing date.
- Form 8-K filings are required to disclose material events such as leadership changes, agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
NRX Pharmaceuticals, Inc.'s stock currently trades at $3.43 with a market capitalization of $37.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for NRX Pharmaceuticals, Inc.'s stock.
All SEC filings for NRX Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View NRXP Stock Page
Frequently Asked Questions
Where can I read NRXP's SEC filings?
Browse all filings on our NRXP SEC filings page.
What types of SEC filings does NRX Pharmaceuticals, Inc. file?
Public companies like NRX Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.